Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryCNS Metastases

Interventions

DRUG

Selinexor

Combination chemotherapy

Trial Locations (2)

RECRUITING

Samsung Cancer Research Institute, Seoul

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

collaborator

Korean Society of Hematology

NETWORK

lead

Samsung Medical Center

OTHER